CN100577167C - 哒嗪并[4,5-b]吲哚-1-乙酰胺衍生物在制备用于治疗与外周型苯并二氮杂䓬受体的失调有关的疾病的药物中的用途 - Google Patents

哒嗪并[4,5-b]吲哚-1-乙酰胺衍生物在制备用于治疗与外周型苯并二氮杂䓬受体的失调有关的疾病的药物中的用途 Download PDF

Info

Publication number
CN100577167C
CN100577167C CN00805273A CN00805273A CN100577167C CN 100577167 C CN100577167 C CN 100577167C CN 00805273 A CN00805273 A CN 00805273A CN 00805273 A CN00805273 A CN 00805273A CN 100577167 C CN100577167 C CN 100577167C
Authority
CN
China
Prior art keywords
chemical compound
indole
general formula
alkyl
neuropathy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN00805273A
Other languages
English (en)
Chinese (zh)
Other versions
CN1344161A (zh
Inventor
B·菲尔扎兹
J·贝纳维德斯
F·马圭特
J·弗罗伊桑特
B·马拉布特
Y·埃范诺
M·塞夫林
P·雅尼尔克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo SA, Sanofi Aventis France filed Critical Sanofi Synthelabo SA
Publication of CN1344161A publication Critical patent/CN1344161A/zh
Application granted granted Critical
Publication of CN100577167C publication Critical patent/CN100577167C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN00805273A 1999-01-26 2000-01-21 哒嗪并[4,5-b]吲哚-1-乙酰胺衍生物在制备用于治疗与外周型苯并二氮杂䓬受体的失调有关的疾病的药物中的用途 Expired - Fee Related CN100577167C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9900806A FR2788696B1 (fr) 1999-01-26 1999-01-26 Utilisation de derives de pyridazino [4,5-b] indole-1-acetamide pour la preparation de medicaments destines aux maladies du systeme nerveux central
FR99/00806 1999-01-26

Publications (2)

Publication Number Publication Date
CN1344161A CN1344161A (zh) 2002-04-10
CN100577167C true CN100577167C (zh) 2010-01-06

Family

ID=9541212

Family Applications (1)

Application Number Title Priority Date Filing Date
CN00805273A Expired - Fee Related CN100577167C (zh) 1999-01-26 2000-01-21 哒嗪并[4,5-b]吲哚-1-乙酰胺衍生物在制备用于治疗与外周型苯并二氮杂䓬受体的失调有关的疾病的药物中的用途

Country Status (32)

Country Link
US (1) US6395729B1 (https=)
EP (1) EP1148881B1 (https=)
JP (1) JP4688295B2 (https=)
KR (1) KR100694752B1 (https=)
CN (1) CN100577167C (https=)
AR (1) AR022413A1 (https=)
AT (1) ATE335487T1 (https=)
AU (1) AU764445B2 (https=)
BG (1) BG65152B1 (https=)
BR (1) BR0007718A (https=)
CA (1) CA2360754C (https=)
CO (1) CO5160242A1 (https=)
CY (1) CY1106257T1 (https=)
CZ (1) CZ294283B6 (https=)
DE (1) DE60029929T2 (https=)
DK (1) DK1148881T3 (https=)
EE (1) EE04905B1 (https=)
ES (1) ES2269097T3 (https=)
FR (1) FR2788696B1 (https=)
HK (1) HK1040905B (https=)
HU (1) HU228670B1 (https=)
IL (2) IL144181A0 (https=)
NO (1) NO321997B1 (https=)
NZ (1) NZ512981A (https=)
PL (1) PL193420B1 (https=)
PT (1) PT1148881E (https=)
RU (1) RU2243764C2 (https=)
SK (1) SK285707B6 (https=)
TR (1) TR200102134T2 (https=)
TW (1) TW541177B (https=)
UA (1) UA70349C2 (https=)
WO (1) WO2000044384A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1329493A (zh) * 1998-12-02 2002-01-02 辉瑞产品公司 恢复p53家族蛋白质的构象稳定性的方法和组合物
FR2811897A1 (fr) * 2000-07-24 2002-01-25 Sanofi Synthelabo UTILISATION DE DERIVES DE PYRIDAZINO[4,5-b]INDOLE-1- ACETAMIDE POUR LA PREPARATION DE MEDICAMENTS DESTINES AU TRAITEMENT DES DYSFONCTIONNEMENTS DES RECEPTEURS DE TYPE PERIPHERIQUE AUX BENZODIAZEPINES
FR2838124B1 (fr) 2002-04-03 2004-05-28 Sanofi Synthelabo Derives de 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino [4,5-b]indole-1-acetamide, leur preparation et leur application en therapeutique
FR2876715B1 (fr) 2004-10-19 2006-12-15 Profiles Du Ct Sa Embout de protection pour ecran de glissiere de securite routiere
GT200600005A (es) * 2005-01-12 2006-08-16 Un derivado de 2-(aminocarbonilo ciclico)-indolina y una composicion farmaceutica que lo contiene
CN101252914B (zh) * 2005-05-05 2013-03-27 塞诺菲-安万特美国有限责任公司 稳定的纳米粒制剂
BRPI0615259A2 (pt) * 2005-08-29 2011-05-17 Sanofi Aventis Us Llc forma cristalina de um derivado de piridazino[4,5-b] indol
CN101272767B (zh) * 2005-08-29 2012-08-29 赛诺菲-安万特美国有限责任公司 7-氯-N,N,5-三甲基-4-氧-3-苯基-3,5-二氢-4H-哒嗪并[4,5-b]吲哚-1-乙酰胺的无定形固体分散体
CN1946120B (zh) * 2006-10-20 2010-05-12 华为技术有限公司 实现话单关联的方法及系统
FR2918563B1 (fr) 2007-07-12 2009-12-04 Oreal Composition photoprotectrice fluide aqueuse a base d'un polymere polyamide a terminaison amide tertiaire.
FR2931064B1 (fr) 2008-05-14 2010-08-13 Oreal Composition cosmetique contenant un derive de dibenzoylmethane et un derive de pyrrolidinone; procede de photostabilisation du derive de dibenzoylmethane
CA2734448A1 (en) * 2008-08-18 2010-02-25 Sanofi-Aventis U.S. Llc Process for preparing polymorph of 7-chloro-n, n,5-trimethyl-4-oxo-3-phenyl-3,5-dihydr0-4h-pyridazin0[4,5-b]indole-1-acetamide
GB0818738D0 (en) * 2008-10-13 2008-11-19 Ge Healthcare Ltd Imaging neuroflammation
FR2936706B1 (fr) 2008-10-08 2010-12-17 Oreal Composition cosmetique contenant un derive de dibenzoylmethane et un compose dithiolane ; procede de photostabilisation du derive de dibenzoylmethane
EP2181717A1 (en) * 2008-10-28 2010-05-05 Sanofi-Aventis Use of 7-chloro-N,N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4,5-B]indole-1-acetamide as a biomarker of peripheral benzodiazepine receptor levels
WO2011073279A2 (fr) 2009-12-18 2011-06-23 L'oreal Procédé de traitement cosmétique impliquant un composé apte à condenser in situ
FR2960773B1 (fr) 2010-06-03 2015-12-11 Oreal Procedes de traitement cosmetique utilisant un revetement a base d'un polymere polyamide-polyether
WO2019113248A1 (en) * 2017-12-07 2019-06-13 The Regents Of The University Of California Anti-upar antibody-drug conjugates and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2298522A1 (en) * 1997-07-30 1999-02-11 Sanofi-Synthelabo 4-oxo-3,5-dihydro-4h-pyridazino[4,5-b]-indole-1-acetamide derivatives, their preparation and their application in therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3121137A1 (de) * 1981-05-27 1982-12-16 Hoechst Ag, 6000 Frankfurt Neue pyridazino(4,5-b)indole, verfahren zu ihrer herstellung, ihre verwendung sowie pharmazeutische praeparate auf basis dieser verbindungen, zwischenprodukte und deren herstellung"
GB9411955D0 (en) * 1994-06-15 1994-08-03 Merck Sharp & Dohme Therapeutic agents
FR2754262B1 (fr) * 1996-10-08 1998-10-30 Synthelabo Derives de 1h-pyrido[3,4-b]indole-4-carboxamide, leur preparation et leur application en therapeutique
US6069267A (en) * 1997-07-29 2000-05-30 E. I. Du Pont De Nemours And Company Selective synthesis of organodiphosphite compounds
FR2788776B1 (fr) * 1999-01-26 2001-02-23 Synthelabo Derives de 4-oxo-3, 5-dihydro-4h-pyridazino [4,5-b] indole-1 -carboxamide, leur preparation et leur application en therapeutique

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2298522A1 (en) * 1997-07-30 1999-02-11 Sanofi-Synthelabo 4-oxo-3,5-dihydro-4h-pyridazino[4,5-b]-indole-1-acetamide derivatives, their preparation and their application in therapy

Also Published As

Publication number Publication date
UA70349C2 (en) 2004-10-15
FR2788696B1 (fr) 2004-03-05
WO2000044384A1 (fr) 2000-08-03
ATE335487T1 (de) 2006-09-15
CA2360754A1 (en) 2000-08-03
TW541177B (en) 2003-07-11
DE60029929D1 (de) 2006-09-21
CN1344161A (zh) 2002-04-10
CZ20012681A3 (cs) 2001-10-17
DE60029929T2 (de) 2007-08-30
HUP0201280A3 (en) 2004-12-28
CA2360754C (en) 2008-07-08
CY1106257T1 (el) 2011-06-08
PT1148881E (pt) 2006-12-29
KR20010089624A (ko) 2001-10-06
EE200100388A (et) 2002-12-16
KR100694752B1 (ko) 2007-03-14
NO321997B1 (no) 2006-07-31
PL349364A1 (en) 2002-07-15
AR022413A1 (es) 2002-09-04
DK1148881T3 (da) 2006-12-11
ES2269097T3 (es) 2007-04-01
NO20013645L (no) 2001-09-26
CO5160242A1 (es) 2002-05-30
EE04905B1 (et) 2007-10-15
SK10502001A3 (sk) 2002-01-07
BG105728A (en) 2002-02-28
PL193420B1 (pl) 2007-02-28
HUP0201280A2 (en) 2002-08-28
JP4688295B2 (ja) 2011-05-25
CZ294283B6 (cs) 2004-11-10
EP1148881A1 (fr) 2001-10-31
AU3057900A (en) 2000-08-18
TR200102134T2 (tr) 2003-03-21
HK1040905A1 (en) 2002-06-28
JP2002535370A (ja) 2002-10-22
HU228670B1 (en) 2013-05-28
IL144181A0 (en) 2002-05-23
RU2243764C2 (ru) 2005-01-10
NO20013645D0 (no) 2001-07-24
EP1148881B1 (fr) 2006-08-09
AU764445B2 (en) 2003-08-21
FR2788696A1 (fr) 2000-07-28
BG65152B1 (bg) 2007-04-30
US6395729B1 (en) 2002-05-28
NZ512981A (en) 2002-10-25
IL144181A (en) 2007-06-17
HK1040905B (zh) 2007-02-23
BR0007718A (pt) 2001-11-13
SK285707B6 (sk) 2007-06-07

Similar Documents

Publication Publication Date Title
CN100577167C (zh) 哒嗪并[4,5-b]吲哚-1-乙酰胺衍生物在制备用于治疗与外周型苯并二氮杂䓬受体的失调有关的疾病的药物中的用途
CN103443085A (zh) 喹唑啉二酮及其应用
TW201919612A (zh) 包含帕博西尼（ｐａｌｂｏｃｉｃｌｉｂ）及６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧基苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－甲酸的組合
DE2428858A1 (de) 1,3-disubstituierte 2,4(1h,3h)chinazolin-derivate
JP2001506981A (ja) α―２アドレナリン受容体作動薬として有用な２―イミダゾリニルアミノインドール化合物
AU764942B2 (en) (2-imidazolin-2-ylamino) quinoxaline derivatives for the treatment of pain
US20210260036A1 (en) Methods of treatment for alpha-1 antitrypsin deficiency
CN100430383C (zh) 可用于治疗性功能障碍的苯并咪唑
JP2002539071A (ja) 新規ｄｎａ開裂抗腫瘍剤
CN111671771B (zh) 靶向dna大沟并抑制拓扑异构酶的石墨烯碱及其制法和用途
CZ81696A3 (en) Xanthine derivatives, process of their preparation and pharmaceutical composition containing thereof
CN108822126B (zh) 噻吩并噻喃甲酰基哌嗪类化合物及其医药用途
JP2011520934A (ja) 筋ジストロフィー治療用化合物
JP4828142B2 (ja) 新規な融合ピラゾリル化合物
EP4009973B1 (en) Pharmaceutical compositions of (6as)-6-methyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-10,11-diol
IL298864A (en) Alkenyl pyrimidine compound, preparation method therefor, and application thereof
HRP20040911A2 (en) 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino[4,5-b]indole-1-acetamide derivatives, preparation and use thereof in medicaments
JPH1045588A (ja) ピラゾロン系化合物またはその塩を含有するα−グルコシダーゼ阻害剤
CN119263971A (zh) 一类环戊烯酮化合物及其盐的制备方法和治疗脑卒中的应用
CN116789646A (zh) 咔唑-苯并咪唑偶联类化合物及其应用
CN113166064A (zh) 胆碱酯酶抑制剂多晶型及其应用
WO2007000771A2 (en) Fused quinazolinone derivatives and uses thereof
MXPA01007550A (en) USE OF PYRIDAZINO[4,5-b
JPWO1999039719A1 (ja) 虚血再灌流障害予防および治療剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20100106

Termination date: 20180121